MeSH term
Frequency | Condition_Probility | Adult | 62 | 0.0 |
Aged | 41 | 0.0 |
Aged, 80 and over | 15 | 0.0 |
Female | 96 | 0.0 |
Humans | 286 | 0.0 |
Immunohistochemistry | 39 | 0.0 |
Male | 86 | 0.0 |
Middle Aged | 56 | 0.0 |
Prognosis | 21 | 0.0 |
Research Support, Non-U.S. Gov't | 172 | 0.0 |
Time Factors | 6 | 0.0 |
Case-Control Studies | 4 | 0.0 |
European Continental Ancestry Group/genetics | 3 | 0.0 |
Gene Frequency | 8 | 0.0 |
Genes, MDR/*genetics | 5 | 15.0 |
Genotype | 5 | 0.0 |
P-Glycoprotein/metabolism | 7 | 11.0 |
Polymorphism, Genetic | 10 | 0.0 |
Reference Values | 3 | 0.0 |
Animals | 74 | 0.0 |
Cell Line | 17 | 0.0 |
Dogs | 4 | 0.0 |
Mice | 37 | 0.0 |
Oxidation-Reduction | 3 | 0.0 |
Rats | 12 | 0.0 |
Rats, Sprague-Dawley | 2 | 0.0 |
Swine | 5 | 0.0 |
Area Under Curve | 3 | 0.0 |
Biological Availability | 5 | 1.0 |
Cross-Over Studies | 2 | 0.0 |
Dose-Response Relationship, Drug | 12 | 0.0 |
P-Glycoprotein/antagonists & inhibitors | 2 | 20.0 |
Antineoplastic Agents/therapeutic use | 2 | 0.0 |
Drug Resistance, Multiple | 27 | 17.0 |
Drug Resistance, Neoplasm | 27 | 5.0 |
Radiopharmaceuticals/*diagnostic use | 2 | 4.0 |
Technetium Tc 99m Sestamibi/*diagnostic use | 3 | 25.0 |
Tomography, Emission-Computed, Single-Photon | 2 | 3.0 |
Biopsy | 5 | 0.0 |
Chronic Disease | 2 | 0.0 |
Comparative Study | 37 | 0.0 |
Gene Expression | 7 | 0.0 |
Genes, MDR/genetics | 3 | 27.0 |
KB Cells | 8 | 9.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Mice, Nude | 4 | 0.0 |
Neoplasm Transplantation | 4 | 0.0 |
P-Glycoprotein/genetics/metabolism | 2 | 16.0 |
Radiopharmaceuticals/diagnostic use/pharmacokinetics | 2 | 8.0 |
Reproducibility of Results | 3 | 0.0 |
Sensitivity and Specificity | 7 | 0.0 |
Tissue Distribution | 5 | 0.0 |
Antineoplastic Agents/pharmacokinetics | 3 | 33.0 |
Clinical Trials | 3 | 0.0 |
Drug Interactions | 6 | 0.0 |
Gene Expression Regulation, Neoplastic/drug effects | 4 | 0.0 |
Genes, MDR | 7 | 21.0 |
Mice, Knockout | 7 | 0.0 |
Rhodamines/pharmacokinetics | 3 | 42.0 |
Technetium Tc 99m Sestamibi/diagnostic use/pharmacokinetics | 2 | 100.0 |
Tumor Cells, Cultured/drug effects/metabolism | 3 | 1.0 |
Adenosine Triphosphate/metabolism | 6 | 1.0 |
Binding Sites | 9 | 0.0 |
Biological Transport, Active | 4 | 2.0 |
Catalysis | 4 | 0.0 |
Dimerization | 3 | 0.0 |
Drug Resistance, Multiple/*physiology | 3 | 12.0 |
Hydrolysis | 4 | 0.0 |
Hydrophobicity | 2 | 2.0 |
Models, Molecular | 3 | 0.0 |
Protein Binding | 6 | 0.0 |
Protein Conformation | 8 | 0.0 |
Protein Structure, Tertiary | 3 | 0.0 |
Structure-Activity Relationship | 8 | 0.0 |
Anticonvulsants/*pharmacokinetics | 2 | 20.0 |
Blood-Brain Barrier/*physiology | 2 | 5.0 |
Epilepsy/*drug therapy/metabolism | 2 | 100.0 |
Gene Expression Regulation | 3 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 60 | 0.0 |
Species Specificity | 3 | 0.0 |
Substrate Specificity | 6 | 0.0 |
Drug Evaluation, Preclinical | 2 | 1.0 |
*Drug Resistance, Multiple | 28 | 27.0 |
Molecular Structure | 6 | 0.0 |
P-Glycoprotein/*antagonists & inhibitors/physiology | 2 | 66.0 |
Alleles | 9 | 0.0 |
*Genes, MDR | 5 | 14.0 |
P-Glycoprotein/*biosynthesis | 10 | 34.0 |
*Polymorphism, Single Nucleotide | 2 | 0.0 |
Antibodies, Monoclonal/immunology | 3 | 0.0 |
Blood-Brain Barrier | 2 | 3.0 |
P-Glycoprotein/*analysis/physiology | 2 | 100.0 |
Daunorubicin/pharmacokinetics | 3 | 50.0 |
Verapamil/pharmacology | 20 | 23.0 |
Biological Transport | 16 | 1.0 |
Blotting, Western | 5 | 0.0 |
Cell Polarity | 2 | 1.0 |
*Membrane Transport Proteins | 2 | 0.0 |
Transfection | 14 | 0.0 |
Age Factors | 3 | 0.0 |
Child | 21 | 0.0 |
Fluorescent Antibody Technique | 6 | 0.0 |
Ubiquitin Thiolesterase | 19 | 18.0 |
Amino Acid Sequence | 6 | 0.0 |
Cell Membrane/metabolism | 5 | 0.0 |
Ligands | 2 | 0.0 |
Molecular Sequence Data | 9 | 0.0 |
P-Glycoprotein/chemistry/*metabolism | 2 | 50.0 |
Radioligand Assay | 3 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Tumor Cells, Cultured | 61 | 0.0 |
ATP-Binding Cassette Transporters/*metabolism | 4 | 4.0 |
Adenosine Triphosphate/*metabolism | 3 | 3.0 |
Diffusion | 2 | 2.0 |
Patch-Clamp Techniques | 2 | 0.0 |
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use | 5 | 1.0 |
Disease-Free Survival | 9 | 0.0 |
Doxorubicin/administration & dosage | 2 | 1.0 |
Follow-Up Studies | 2 | 0.0 |
Proportional Hazards Models | 2 | 0.0 |
Prospective Studies | 4 | 0.0 |
Survival Rate | 3 | 0.0 |
Vincristine/administration & dosage | 2 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 10 | 0.0 |
Vinblastine/metabolism | 2 | 33.0 |
Antineoplastic Agents/pharmacology | 12 | 2.0 |
Cell Division/drug effects | 5 | 0.0 |
Doxorubicin/pharmacology | 12 | 5.0 |
Drug Resistance, Neoplasm/genetics | 3 | 4.0 |
Gene Expression Regulation, Neoplastic | 12 | 0.0 |
P-Glycoprotein/*genetics | 9 | 19.0 |
Paclitaxel/pharmacology | 2 | 2.0 |
RNA, Messenger/genetics/metabolism | 3 | 0.0 |
Tumor Cells, Cultured/drug effects | 8 | 1.0 |
Rhodamine 123/metabolism | 2 | 28.0 |
Survival Analysis | 9 | 0.0 |
Tumor Cells, Cultured/metabolism | 3 | 1.0 |
Antibodies, Monoclonal/*pharmacology | 3 | 1.0 |
Base Sequence | 7 | 0.0 |
CHO Cells | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Hamsters | 8 | 0.0 |
P-Glycoprotein/*antagonists & inhibitors | 8 | 66.0 |
*Drug Resistance, Multiple/genetics | 5 | 55.0 |
Algorithms | 2 | 0.0 |
Antineoplastic Agents, Phytogenic/*pharmacokinetics | 2 | 22.0 |
Breast Neoplasms/metabolism | 2 | 1.0 |
Models, Biological | 3 | 0.0 |
P-Glycoprotein/*physiology | 8 | 36.0 |
Paclitaxel/*pharmacokinetics | 2 | 50.0 |
Antineoplastic Agents, Phytogenic/*pharmacology | 3 | 1.0 |
Doxorubicin/*pharmacokinetics | 3 | 75.0 |
Erythrocytes/*metabolism | 2 | 0.0 |
K562 Cells | 6 | 1.0 |
Multidrug Resistance-Associated Proteins | 17 | 23.0 |
Cyclosporine/*pharmacology | 3 | 2.0 |
Immunosuppressive Agents/pharmacology | 2 | 1.0 |
In Vitro | 9 | 0.0 |
P-Glycoprotein/*antagonists & inhibitors/metabolism | 2 | 22.0 |
ATP-Binding Cassette Transporters/*genetics | 3 | 1.0 |
Cell Division | 4 | 0.0 |
*Drug Resistance, Neoplasm | 12 | 7.0 |
Etoposide/pharmacology | 2 | 1.0 |
Isoenzymes/genetics | 3 | 0.0 |
P-Glycoprotein/genetics | 3 | 9.0 |
3T3 Cells | 10 | 0.0 |
Caco-2 Cells | 4 | 1.0 |
Cells, Cultured | 10 | 0.0 |
P-Glycoprotein/genetics/*metabolism | 7 | 35.0 |
Binding Sites/physiology | 2 | 1.0 |
P-Glycoprotein/biosynthesis/*metabolism | 2 | 50.0 |
Japan | 2 | 0.0 |
Linkage (Genetics) | 3 | 0.0 |
Polymerase Chain Reaction | 6 | 0.0 |
Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Multidrug Resistance-Associated Proteins/metabolism | 2 | 20.0 |
Proto-Oncogene Proteins c-bcl-2/metabolism | 3 | 0.0 |
Tumor Markers, Biological/*analysis | 2 | 0.0 |
Brain/*metabolism | 2 | 0.0 |
Calcium Channel Blockers/pharmacology | 4 | 4.0 |
Flow Cytometry | 18 | 0.0 |
P-Glycoprotein/*metabolism | 22 | 28.0 |
Antibiotics, Antineoplastic/pharmacology | 2 | 2.0 |
Biological Transport/drug effects | 3 | 1.0 |
Doxorubicin/*pharmacology | 3 | 4.0 |
Buthionine Sulfoximine/toxicity | 3 | 100.0 |
Drug Synergism | 4 | 0.0 |
HL-60 Cells | 2 | 0.0 |
Amino Acid Substitution/genetics | 2 | 0.0 |
Antibodies, Monoclonal/metabolism | 2 | 0.0 |
Antigen-Antibody Reactions/drug effects | 2 | 14.0 |
Drug Resistance, Multiple/*genetics | 8 | 12.0 |
Protein Conformation/drug effects | 3 | 5.0 |
Adenosine Triphosphate/analogs & derivatives/pharmacology | 2 | 25.0 |
Carrier Proteins/genetics | 2 | 0.0 |
Vinblastine/pharmacology | 6 | 16.0 |
*Cell Cycle Proteins | 2 | 0.0 |
Drug Resistance, Multiple/genetics | 4 | 9.0 |
Glutathione/metabolism | 3 | 1.0 |
Hydrogen Peroxide/pharmacology | 2 | 0.0 |
Kinetics | 10 | 0.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Drug Resistance, Neoplasm/*genetics | 4 | 4.0 |
Quinolines/*pharmacology/therapeutic use | 2 | 40.0 |
*Bacterial Proteins | 2 | 1.0 |
English Abstract | 10 | 0.0 |
Blood Proteins/*genetics | 5 | 3.0 |
Haplotypes | 2 | 0.0 |
Italy | 4 | 0.0 |
Phenotype | 24 | 0.0 |
Phosphoric Monoester Hydrolases/*genetics | 14 | 6.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Temperature | 3 | 0.0 |
Cytochrome P-450 Enzyme System/genetics/*metabolism | 2 | 1.0 |
Mixed Function Oxygenases/genetics/*metabolism | 2 | 4.0 |
Acridines/pharmacology | 2 | 33.0 |
Cyclosporins/pharmacology | 7 | 18.0 |
Isoquinolines/pharmacology | 3 | 2.0 |
*Tetrahydroisoquinolines | 4 | 6.0 |
Immunoenzyme Techniques | 7 | 0.0 |
*Depsipeptides | 2 | 6.0 |
Molecular Conformation | 3 | 1.0 |
Daunorubicin/metabolism | 2 | 50.0 |
Microscopy, Fluorescence | 2 | 0.0 |
P-Glycoprotein/drug effects/*metabolism | 2 | 50.0 |
Stereoisomerism | 4 | 1.0 |
Adolescent | 22 | 0.0 |
Antineoplastic Agents, Phytogenic/pharmacology | 3 | 3.0 |
Combined Modality Therapy | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Verapamil/*pharmacology | 2 | 6.0 |
Vincristine/pharmacology | 4 | 7.0 |
Intestines/metabolism | 2 | 1.0 |
RNA, Messenger/metabolism | 4 | 0.0 |
Antineoplastic Agents/*therapeutic use | 4 | 1.0 |
Doxorubicin/therapeutic use | 2 | 3.0 |
Muscle, Smooth/innervation | 2 | 18.0 |
ATP-Binding Cassette Transporters/physiology | 2 | 22.0 |
Acute Disease | 8 | 0.0 |
P-Glycoprotein/physiology | 3 | 42.0 |
RNA, Messenger/biosynthesis | 4 | 0.0 |
RNA, Neoplasm/biosynthesis | 2 | 1.0 |
Biological Markers | 8 | 0.0 |
Neoplasm Proteins/*analysis | 7 | 2.0 |
Predictive Value of Tests | 5 | 0.0 |
Retrospective Studies | 4 | 0.0 |
ATP-Binding Cassette Transporters/*physiology | 3 | 13.0 |
Calcium/metabolism | 2 | 0.0 |
Isoquinolines/*pharmacology | 2 | 7.0 |
Microscopy, Confocal | 2 | 0.0 |
Rhodamines/metabolism | 5 | 23.0 |
Neuropeptides/*metabolism | 4 | 4.0 |
Nitric-Oxide Synthase/*metabolism | 2 | 2.0 |
Cyclic AMP-Dependent Protein Kinases/metabolism | 2 | 1.0 |
Liposomes | 3 | 1.0 |
Spectrometry, Fluorescence | 2 | 0.0 |
Cyclosporine/pharmacology | 11 | 5.0 |
Glomerular Mesangium/cytology/drug effects/*secretion | 2 | 100.0 |
Platelet Activating Factor/pharmacology/*secretion | 2 | 100.0 |
Rhodamine 123/pharmacokinetics | 3 | 37.0 |
P-Glycoprotein/*analysis/genetics | 2 | 40.0 |
Biological Markers/analysis | 5 | 0.0 |
Colon/*innervation | 2 | 15.0 |
Neuropeptides/analysis | 2 | 10.0 |
Thiolester Hydrolases/*analysis | 2 | 28.0 |
Microcirculation/physiology | 2 | 6.0 |
Child, Preschool | 9 | 0.0 |
Fluorescent Antibody Technique, Indirect | 5 | 0.0 |
Leukemia, Myeloid/*drug therapy | 2 | 16.0 |
P-Glycoprotein/analysis/*genetics | 3 | 75.0 |
Cell Nucleus/metabolism | 2 | 0.0 |
P-Glycoprotein/*genetics/metabolism | 4 | 36.0 |
Cytarabine/administration & dosage | 3 | 3.0 |
Disease Progression | 2 | 0.0 |
Karyotyping | 3 | 0.0 |
Mitoxantrone/administration & dosage | 2 | 7.0 |
Remission Induction | 2 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
*Multidrug Resistance-Associated Proteins | 2 | 3.0 |
Nerve Tissue Proteins/analysis | 4 | 5.0 |
Thiolester Hydrolases/analysis | 9 | 25.0 |
ATP-Binding Cassette Transporters/genetics/*metabolism | 2 | 3.0 |
Adenocarcinoma | 4 | 3.0 |
Breast Neoplasms | 3 | 1.0 |
Lung Neoplasms | 3 | 2.0 |
Daunorubicin/pharmacology | 3 | 12.0 |
Drug Resistance | 5 | 0.0 |
Antineoplastic Agents/*pharmacology | 10 | 1.0 |
Apoptosis/*drug effects | 2 | 0.0 |
Cyclosporins/*pharmacology | 5 | 14.0 |
Dibenzocycloheptenes/*pharmacology | 2 | 66.0 |
Peptides, Cyclic/*pharmacology | 2 | 9.0 |
Quinolines/*pharmacology | 3 | 10.0 |
Daunorubicin/therapeutic use | 2 | 14.0 |
Multiple Myeloma/*drug therapy | 2 | 12.0 |
Azides/antagonists & inhibitors/metabolism | 2 | 100.0 |
Hela Cells | 3 | 0.0 |
Iodine Radioisotopes/metabolism | 3 | 8.0 |
Photoaffinity Labels/metabolism | 3 | 30.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Nerve Fibers/chemistry | 2 | 12.0 |
Nerve Tissue Proteins/*analysis | 3 | 3.0 |
Infant | 11 | 0.0 |
Infant, Newborn | 4 | 0.0 |
*Chromosome Aberrations | 2 | 0.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
Quinolines/pharmacology | 2 | 9.0 |
*Apoptosis | 2 | 0.0 |
P-Glycoprotein/analysis | 5 | 20.0 |
Paclitaxel/*pharmacology | 2 | 3.0 |
Protein p53/analysis | 3 | 1.0 |
Proto-Oncogene Proteins c-bcl-2/analysis | 3 | 1.0 |
ATP-Binding Cassette Transporters/analysis | 2 | 28.0 |
P-Glycoprotein/*analysis | 6 | 35.0 |
Protein p53/*biosynthesis | 2 | 1.0 |
Antibiotics, Antineoplastic/*pharmacology | 3 | 2.0 |
*Liver Transplantation | 2 | 1.0 |
Adenosinetriphosphatase/metabolism | 4 | 3.0 |
Vinblastine/pharmacokinetics | 2 | 50.0 |
Fatal Outcome | 2 | 0.0 |
Colchicine/pharmacology | 4 | 6.0 |
Fluorescent Dyes/metabolism | 2 | 2.0 |
Point Mutation | 2 | 0.0 |
Cell Survival/drug effects | 6 | 0.0 |
Drug Screening Assays, Antitumor | 5 | 1.0 |
Cell Line, Tumor | 2 | 0.0 |
P-Glycoprotein/biosynthesis/*genetics | 2 | 28.0 |
Neoplasm Staging | 3 | 0.0 |
Antibodies, Monoclonal | 7 | 0.0 |
*Vault Ribonucleoprotein Particles | 3 | 42.0 |
Recombinant Proteins | 2 | 0.0 |
Chromatography, Affinity | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Spodoptera | 2 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
P-Glycoprotein/biosynthesis | 3 | 13.0 |
Biological Transport/physiology | 2 | 1.0 |
Gene Expression/genetics | 2 | 0.0 |
*P-Glycoproteins | 3 | 37.0 |
Rats, Wistar | 2 | 0.0 |
Acid Phosphatase/genetics | 2 | 6.0 |
Adenosine Deaminase/genetics | 2 | 9.0 |
Adenylate Kinase/genetics | 2 | 8.0 |
Erythrocytes/enzymology | 4 | 1.0 |
*Gene Frequency | 4 | 0.0 |
Phosphoric Monoester Hydrolases/genetics | 2 | 2.0 |
Antineoplastic Combined Chemotherapy Protocols/therapeutic use | 5 | 1.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Fluoresceins/metabolism | 4 | 19.0 |
Neoplasm Proteins/*metabolism | 3 | 0.0 |
Rhodamine 123 | 5 | 20.0 |
Gene Expression Regulation, Neoplastic/*physiology | 2 | 1.0 |
Antineoplastic Agents, Phytogenic/therapeutic use | 2 | 14.0 |
Prazosin/*analogs & derivatives/metabolism | 2 | 100.0 |
Recurrence | 2 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Mutation | 3 | 0.0 |
Antineoplastic Agents/metabolism/*pharmacology | 2 | 7.0 |
P-Glycoprotein/*biosynthesis/genetics | 2 | 15.0 |
Antigens, CD56/*analysis | 2 | 6.0 |
Cisplatin/administration & dosage | 3 | 1.0 |
Cyclophosphamide/administration & dosage | 2 | 0.0 |
Gestational Age | 2 | 0.0 |
Thiolester Hydrolases/metabolism | 2 | 11.0 |
*Drug Resistance, Neoplasm/genetics | 2 | 22.0 |
Gene Expression Regulation, Neoplastic/*drug effects | 2 | 0.0 |
Blotting, Northern | 2 | 0.0 |
Glutathione Transferase/metabolism | 2 | 0.0 |
Biological Transport, Active/drug effects | 2 | 3.0 |
Drug Resistance, Multiple/physiology | 2 | 33.0 |
Immunohistochemistry/methods | 5 | 0.0 |
Antigens, CD/analysis | 2 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Doxorubicin/*analogs & derivatives/*pharmacology | 2 | 66.0 |
Disease Models, Animal | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Apoptosis/drug effects | 4 | 0.0 |
Leukemia, Lymphocytic, Acute/*drug therapy | 2 | 14.0 |
P-Glycoprotein | 15 | 32.0 |
Calcitonin Gene-Related Peptide/metabolism | 3 | 8.0 |
Neurons/*metabolism | 2 | 0.0 |
Neuropeptide Y/metabolism | 2 | 3.0 |
Tyrosine 3-Monooxygenase/metabolism | 2 | 1.0 |
*Genetics, Population | 2 | 0.0 |
Pregnancy | 2 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
Treatment Outcome | 5 | 0.0 |
P-Glycoprotein/antagonists & inhibitors/*physiology | 2 | 40.0 |
Multivariate Analysis | 2 | 0.0 |
Sex Factors | 2 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Immunoblotting | 3 | 0.0 |
Calcitonin Gene-Related Peptide/analysis | 6 | 8.0 |
Substance P/analysis | 5 | 5.0 |
Neuropeptides/analysis/*metabolism | 2 | 50.0 |
Fluorescence | 2 | 0.0 |
Drug Resistance/genetics | 5 | 3.0 |
*Multigene Family | 3 | 0.0 |
Neuropeptides/*analysis | 3 | 3.0 |
Neoplasm Proteins/*genetics | 2 | 0.0 |
Piperidines/*pharmacology | 2 | 3.0 |
Erythrocytes/*enzymology | 5 | 0.0 |
Europe | 2 | 0.0 |
*Genetic Markers | 4 | 1.0 |
*Polymorphism, Genetic | 7 | 0.0 |
DNA Primers/chemistry | 2 | 0.0 |
Dopamine beta-Hydroxylase/analysis | 2 | 9.0 |
*Embryonic and Fetal Development | 2 | 1.0 |
Neuropeptide Y/analysis | 2 | 2.0 |
Vasoactive Intestinal Peptide/analysis | 2 | 2.0 |
Neoplasm Recurrence, Local | 2 | 0.0 |
Brain Neoplasms/*metabolism | 2 | 2.0 |
Vault Ribonucleoprotein Particles/*metabolism | 2 | 28.0 |
Binding, Competitive | 2 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
*Chromosomes, Human, Pair 16 | 6 | 2.0 |
Genes, Dominant | 3 | 0.0 |
Genetic Markers | 10 | 0.0 |
Lod Score | 5 | 0.0 |
Pedigree | 5 | 0.0 |
Carrier Proteins/*genetics | 3 | 0.0 |
Membrane Proteins/genetics | 2 | 0.0 |
Mice, Inbred NOD | 2 | 0.0 |
Mice, SCID | 2 | 0.0 |
Xenograft Model Antitumor Assays | 3 | 1.0 |
*Drug Resistance | 3 | 6.0 |
Membrane Glycoproteins/*genetics | 3 | 0.0 |
Drug Carriers | 2 | 1.0 |
Phosphorylation | 2 | 0.0 |
Neoplasm Proteins/metabolism | 5 | 1.0 |
Blood Group Antigens/*genetics | 2 | 1.0 |
Substance P/metabolism | 2 | 3.0 |
Gene Expression/drug effects | 2 | 0.0 |
Bone Marrow/pathology | 3 | 0.0 |
Membrane Glycoproteins/*metabolism | 2 | 0.0 |
Membrane Glycoproteins/genetics/*physiology | 2 | 2.0 |
Cricetulus | 2 | 0.0 |
Variation (Genetics) | 3 | 0.0 |
Risk Factors | 2 | 0.0 |
Molecular Weight | 2 | 0.0 |
Polycystic Kidney Diseases/*genetics | 3 | 8.0 |
Recombination, Genetic | 4 | 0.0 |
*Alleles | 2 | 0.0 |
DNA Primers | 2 | 0.0 |
Cell Cycle | 2 | 0.0 |
Breast Neoplasms/drug therapy/*metabolism | 2 | 9.0 |
Hybrid Cells | 4 | 0.0 |
*Phenotype | 2 | 0.0 |
Enzymes/blood/*genetics | 2 | 33.0 |
Haptoglobins/*genetics | 2 | 5.0 |
*Linkage (Genetics) | 5 | 0.0 |
Electrophoresis, Starch Gel | 6 | 4.0 |
Chromosomes, Human, 16-18 | 2 | 18.0 |
2,3-Diphosphoglycerate | 2 | 14.0 |
Hemoglobinometry | 2 | 6.0 |
Phosphoric Monoester Hydrolases/*blood | 3 | 42.0 |
Heat | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
P-Glycoproteins/metabolism/physiology | 2 | 100.0 |
*Chromosomes, Human, 16-18 | 2 | 10.0 |
Glycolates | 2 | 100.0 |
*Membrane Glycoproteins | 2 | 0.0 |
